Safety and Tolerability of a 'Refrigeration-free' Formulation of Interferon Beta-1b – Results of a Double-blind, Multicentre, Comparative Study in Patients with Relapsing–Remitting or Secondary Progressive Multiple Sclerosis

By Baum K    

The Journal of International Medical Research, Vol. 34, Iss. 1, 2006-01 ,pp. : 1-12

Field House Publishing

Access to resources Recommend Favorite

Interferon- -1b: A Review of its Use in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis

By McCormack P.L.   Scott L.J.  

CNS Drugs, Vol. 18, Iss. 8, 2004-01 ,pp. : 521-546

Adis International

Access to resources Recommend Favorite

Long-Term Cost Effectiveness of Interferon- -1a in the Treatment of Relapsing-Remitting Multiple Sclerosis: An Econometric Model

By Lepen C.  

Clinical Drug Investigation, Vol. 23, Iss. 9, 2003-01 ,pp. : 571-581

Adis International

Access to resources Recommend Favorite

Subcutaneous Recombinant Interferon- -1a (Rebif®): A Review of its Use in Relapsing-Remitting Multiple Sclerosis

By Murdoch David   Lyseng-Williamson Katherine A.  

Drugs, Vol. 65, Iss. 9, 2005-01 ,pp. : 1295-1312

Adis International

Access to resources Recommend Favorite

Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 16, Iss. 1, 2017-01 ,pp. : 93-101

Bentham Science Publishers

Access to resources Recommend Favorite